HER4在乳腺癌中的表达及临床意义

目的:探讨乳腺癌患者HER4与HER2?ER?PR之间的关系及其对乳腺癌预后的影响?方法:采用免疫组化SP法检测105例乳腺癌组织中HER4?HER2?ER?PR蛋白的表达?对患者随访,随访终点为无病生存时间(disease free survival,DFS)?结果:HER2?HER4?ER?PR在105例乳腺癌患者中的阳性表达率分别为:37.14%?20.00%?40.00%?28.27%;HER4与年龄?淋巴结转移?分期?肿瘤类型以及是否化疗的差异性均无统计学意义(P﹥0.05);HER4可刺激ER?PR产生(P = 0.030,P = 0.028);HER4阳性与阴性患者无病生存时间差异有统计学意义(P = 0.039);HER4(+)HER2(-)组乳腺癌患者较其他组无病生存时间明显延长(P = 0.000)?结论:HER4可作为独立的临床预后因子,HER4可延长乳腺癌患者无病生存时间并可刺激ER?PR的产生?

Expression and clinical significance of HER4 in breast carcinoma

Objective:To investigate the relationship between expression of HER4,HER2,ER and PR and evaluate them on the clinical prognosis of human breast carcinoma. Methods:The expressions of HER4,HER2,ER and PR were studied in 105 cases with breast carcinoma by using SP immunohistochemistry. The endpoint of follow-up was disease free survival(DFS). Results:HER2,HER4,ER and PR expression were detected in 105 cases with positive rates of 37.14%,20.00%,40.00%,28.27%,respectively. The expression intensity of HER2,HER4,ER and PR in breast carcinoma had no significant correlation with the age,lymph node metastasis,pathological types,TNM stage,chemotherapy of the patients(P > 0.05). HER4 can be a co-activator of ER and PR expression(P = 0.030,P = 0.028). Compared with those with HER4-positive profiles,patients with HER4-negative profiles had significantly lower DFS(P = 0.039). Patients with HER4-positive and HER2-negative expression profiles had significantly longer DFS(P = 0.000) than other groups. Conclusion:HER4 expression is an independent predictor of breast cancer. Patients with HER4-positive have longer DFS, and HER4 can be a co-activator of ER and PR.